Moderna, Inc. (MRNA)

24.82
1.19 5.04
NASDAQ
Prev Close 23.63
Open 23.73
Day Low/High 23.73 / 24.98
52 Wk Low/High 13.03 / 24.40
Volume 329.67K
Exchange NASDAQ
Shares Outstanding 329.00B
Market Cap 7.41B
Div & Yield N.A. (N.A)

Latest News

Moderna To Host Science Day On May 7, 2019 And Report First Quarter Financial Results On May 8, 2019

Moderna To Host Science Day On May 7, 2019 And Report First Quarter Financial Results On May 8, 2019

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host its annual Science Day...

McDonald's, Moderna, Twilio: 'Mad Money' Lightning Round

McDonald's, Moderna, Twilio: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at McDonald's, Moderna, Illinois Tool Works, Twilio and more.

Top-Callers Are Back: Cramer's 'Mad Money' Recap (Tuesday 4/9/19)

Top-Callers Are Back: Cramer's 'Mad Money' Recap (Tuesday 4/9/19)

Jim Cramer says a garden-variety pullback is reasonable, but don't be spooked by pundits and portfolio managers.

Moderna To Present At 18th Annual Needham Healthcare Conference

Moderna To Present At 18th Annual Needham Healthcare Conference

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Tal Zaks, M.

Moderna Reports 2018 Fourth Quarter And Full Year Financial Results And Highlights Recent Pipeline Progress

Moderna Reports 2018 Fourth Quarter And Full Year Financial Results And Highlights Recent Pipeline Progress

Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today reported financial results for the fourth quarter and...

Buy or Sell the News?: Cramer's 'Mad Money' Recap (Monday 3/4/19)

Buy or Sell the News?: Cramer's 'Mad Money' Recap (Monday 3/4/19)

Jim Cramer analyzes what's driving the sellers and looks into this out-of-high-growth-into-value rotation.

Moderna To Present At Upcoming Investor Conferences In March

Moderna To Present At Upcoming Investor Conferences In March

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced its participation in the following upcoming...

Moderna To Report Fourth Quarter And Full Year 2018 Financial Results On Wednesday, March 6, 2019

Moderna To Report Fourth Quarter And Full Year 2018 Financial Results On Wednesday, March 6, 2019

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host a live conference call...

Phase 1 Data Published In Nature Communications Show Potential Of MRNA Encoding VEGF-A As A Regenerative Therapeutic

Phase 1 Data Published In Nature Communications Show Potential Of MRNA Encoding VEGF-A As A Regenerative Therapeutic

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the publication of a Phase 1a/b study in...

Moderna's Small Base Could Surprise on the Upside

Moderna's Small Base Could Surprise on the Upside

Prices have moved above the early January high giving us the simple definition of an uptrend.

IPO Explosion: Cramer's 'Mad Money' Recap (Wednesday 2/13/19)

IPO Explosion: Cramer's 'Mad Money' Recap (Wednesday 2/13/19)

Jim Cramer sees ripple effects of a storm of IPOs, and is worried about the lack of money coming into the market.

Fitbit, Moderna, Tilray: 'Mad Money' Lightning Round

Fitbit, Moderna, Tilray: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Fitbit, Moderna, Tilray, Exelixis, Maxar Technology, International Paper and more.

Moderna Announces Positive Interim Phase 1 Data For First Combination Vaccine Against The Respiratory Viruses HMPV And PIV3

Moderna Announces Positive Interim Phase 1 Data For First Combination Vaccine Against The Respiratory Viruses HMPV And PIV3

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced topline data from the first planned interim...

Moderna Announces Dosing Of The First Monoclonal Antibody Encoded By MRNA In A Clinical Trial

Moderna Announces Dosing Of The First Monoclonal Antibody Encoded By MRNA In A Clinical Trial

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the dosing of the first subject in a Phase...

Bulls vs. Bears: Cramer's 'Mad Money' Recap (Friday 2/1/19)

Bulls vs. Bears: Cramer's 'Mad Money' Recap (Friday 2/1/19)

Jim Cramer makes sense of this market action and has your game plan for next week.

Bank of America, Kemet, Boston Beer: 'Mad Money' Lightning Round

Bank of America, Kemet, Boston Beer: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Bank of America, Kemet, Boston Beer, Diageo, Pilgrim's Pride, Tyson Foods, Moderna and more.

Fear of Missing Out Is the Main Driving Force in This Market

Fear of Missing Out Is the Main Driving Force in This Market

Stick to your methodology and don't let worry of underperformance push you to shift your approach.

Newly Published Pre-Clinical Data Show Intratumoral Injections Of Messenger RNA Encoding Three Immune Modulators Stimulate Durable Anti-Cancer Responses In Treated And Distal Tumors

Newly Published Pre-Clinical Data Show Intratumoral Injections Of Messenger RNA Encoding Three Immune Modulators Stimulate Durable Anti-Cancer Responses In Treated And Distal Tumors

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the publication of pre-clinical data that...

Dr. John Mendlein To Transition To An Advisory Role At Moderna And Join Flagship Pioneering As An Executive Partner

Dr. John Mendlein To Transition To An Advisory Role At Moderna And Join Flagship Pioneering As An Executive Partner

Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that John Mendlein, Ph.

Moderna, MyoKardia Are Among Cutting-Edge Biotech Stocks for 2019

Moderna, MyoKardia Are Among Cutting-Edge Biotech Stocks for 2019

Moderna only went public in December, and is already creating a buzz.

Moderna Shares Jump on Positive Cancer-Treatment Progress

Moderna Shares Jump on Positive Cancer-Treatment Progress

Report on positive results of new drugs to treat ovarian and other cancers sends shares higher.

Moderna Announces Recent Progress In Its Immuno-Oncology And Rare Disease Programs And Highlights Corporate Objectives

Moderna Announces Recent Progress In Its Immuno-Oncology And Rare Disease Programs And Highlights Corporate Objectives

Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced recent updates to several of its...

Moderna To Provide Business And Pipeline Updates At The 2019 J.P. Morgan Healthcare Conference

Moderna To Provide Business And Pipeline Updates At The 2019 J.P. Morgan Healthcare Conference

Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced today that CEO Stéphane Bancel will present an...

It's a Two-Sided Market: Cramer's 'Mad Money' Recap (Monday 12/10/18)

It's a Two-Sided Market: Cramer's 'Mad Money' Recap (Monday 12/10/18)

There are two sides, or more, to every market story these days, Jim Cramer says.

Biotech Moderna Slides in Its Trading Debut

Biotech Moderna Slides in Its Trading Debut

Drug developing startup Moderna Inc. raises $604.3 million for an initial public offering running up to its expected Nasdaq debut Friday.

Moderna Announces Pricing Of Initial Public Offering

Moderna Announces Pricing Of Initial Public Offering

Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the pricing of its initial public offering...